Recent events
Recent events tied to this brand in public sources.
Back to profile59 entries · Page 2 of 3
2021
Roche launches SARS-CoV-2 variant test
Roche announced the launch of the cobas SARS-CoV-2 Variant Set 1 Test, a research-use-only laboratory test designed to detect and differentiate mutations found in variants originating in the UK, South Africa and Brazil.
2021
Roche reportedly notifies Rocephin team of layoffs
According to industry sources and Roche employees, the Rocephin antibiotic team received layoff notices requiring employees to leave by March 31; Roche offered internal recruitment opportunities to employees who did not wish to leave.
2021
Affimed and Roche enter clinical research collaboration
Affimed announced a clinical research collaboration with Roche to explore combining Affimed's AFM24 with Roche's atezolizumab (Tecentriq).
2020
Roche and Sysmex renew global partnership
Roche and Sysmex signed a global business partnership agreement on December 14, 2020, renewing their distribution, sales and service agreement and introducing an IT solutions collaboration agreement. The agreement runs through the end of 2030.
2020
FDA approves shorter OCREVUS infusion
Roche announced that the U.S. FDA approved a shorter two-hour infusion time for OCREVUS (ocrelizumab) for eligible people with relapsing or primary progressive multiple sclerosis.
2020
Roche and Diabeloop announce insulin-therapy partnership
Roche announced a partnership with Diabeloop to advance the management of insulin pump therapy. The announcement described the partnership as Roche’s first step into automated insulin delivery.
2020
Roche partners with Moderna on vaccine trials
Roche announced a partnership with Moderna to use Roche’s Elecsys Anti-SARS-CoV-2 S antibody test in Moderna’s mRNA-1273 vaccine research trials.
2020
FDA approves Xolair for adult nasal polyps
The U.S. Food and Drug Administration approved Roche's supplemental application for Xolair as add-on maintenance treatment for adults with nasal polyps who have an inadequate response to nasal corticosteroids.
2020
FDA approves Xofluza for influenza prevention after exposure
The US FDA approved Roche’s supplemental application for Xofluza to prevent influenza in people aged 12 and older following contact with an infected person.
2020
Saphetor partners with Roche Turkey on SMA drug discovery
Saphetor announced a partnership with Roche Turkey centered on supporting Roche's drug discovery initiatives into spinal muscular atrophy. Saphetor will facilitate connections between laboratories interested in partnering with Roche on SMA research.
2020
Roche and Atea announce AT-527 collaboration
Roche and Atea Pharmaceuticals announced a collaboration to develop, manufacture, and distribute AT-527, an investigational oral antiviral being studied for COVID-19. Roche is responsible for distribution outside the United States; Atea is responsible for U.S. distribution, with an option to request Genentech’s support.
2020
Roche acquires Enterprise Therapeutics' TMEM16A potentiator portfolio
Roche acquired Enterprise Therapeutics' TMEM16A potentiator portfolio, which will be developed by Genentech, a member of the Roche Group. Enterprise shareholders are eligible for additional contingent payments tied to predetermined milestones.
2020
Roche completes acquisition of Inflazome
Inflazome announced that it had closed a share purchase agreement with Roche. Inflazome shareholders received an upfront payment of €380 million and are eligible for additional payments tied to predetermined milestones; the acquisition gives Roche full rights to Inflazome's portfolio.
2020
Inflazome announces acquisition by Roche
Inflazome announced its acquisition by Roche for €380 million. Roche said it intends to continue developing Inflazome's inflammasome inhibitors.
2020
Roche test receives FDA emergency use authorization
Roche announced that its cobas SARS-CoV-2 & Influenza A/B Test for use on the cobas 6800/8800 Systems had received Emergency Use Authorization from the FDA.
2020
FDA approves Roche’s Enspryng for NMOSD
The FDA approved Roche’s drug Enspryng for treating neuromyelitis optica spectrum disorder (NMOSD).
2020
FDA approves Roche's ENSPRYNG for NMOSD
The US Food and Drug Administration approved Roche's ENSPRYNG as a treatment for adults with anti-AQP4 antibody positive neuromyelitis optica spectrum disorder (NMOSD).
2020
FDA approves Evrysdi for spinal muscular atrophy
The U.S. Food and Drug Administration approved Roche's Evrysdi (risdiplam) for treatment of spinal muscular atrophy in adults and children aged 2 months and older.
2020
FDA approves Roche's Tecentriq combination for advanced melanoma
Roche announced that the U.S. FDA approved Tecentriq in combination with Cotellic and Zelboraf for patients with BRAF V600 mutation-positive advanced melanoma.
2020
Roche and Blueprint Medicines announce pralsetinib licensing and collaboration agreement
Roche and Blueprint Medicines announced a licensing and collaboration agreement granting Roche exclusive global co-development and commercialisation rights outside the United States, excluding Greater China. Genentech, a Roche Group member, will have US co-commercialisation rights.